Iterum Therapeutics PLC
NASDAQ:ITRM

Watchlist Manager
Iterum Therapeutics PLC Logo
Iterum Therapeutics PLC
NASDAQ:ITRM
Watchlist
Price: 0.363 USD 3.68% Market Closed
Market Cap: $19.2m

Net Margin

-6 913.1%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-6 913.1%
=
Net Income
$-27m
/
Revenue
$390k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-6 913.1%
=
Net Income
$-27m
/
Revenue
$390k

Peer Comparison

Country Company Market Cap Net
Margin
IE
Iterum Therapeutics PLC
NASDAQ:ITRM
17.8m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
529.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.3B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
222B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
269.1B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
145.8B USD
Loading...
FR
Sanofi SA
PAR:SAN
96.9B EUR
Loading...

Market Distribution

Lower than 100% of companies in Ireland
Percentile
0th
Based on 314 companies
0th percentile
-6 913.1%
Low
-6 913.1% — 0%
Typical Range
0% — 10.2%
High
10.2% — 197.7%
Distribution Statistics
Ireland
Min -6 913.1%
30th Percentile 0%
Median 3.1%
70th Percentile 10.2%
Max 197.7%

Iterum Therapeutics PLC
Glance View

Market Cap
19.2m USD
Industry
Pharmaceuticals

Iterum Therapeutics Plc operates as a pharmaceutical company, which engages in the development and commercialization of sulopenem to be potentially the first and only oral and intravenous (IV) branded penem available. The company is headquartered in Dublin, Dublin and currently employs 13 full-time employees. The company went IPO on 2018-05-25. The firm is focused on developing significantly differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant (MDR) pathogens. The firm is developing sulopenem - the oral and intervenous (IV) penem antibiotic demonstrating a potent spectrum of activity against multi-drug resistant gram-negative. The company is a bioavailable, antibiotic covering gram-positive, gram-negative and anaerobic pathogen with in-vitro activity against multidrug-resistant pathogens, including Extended-Spectrum Beta-Lactamase (ESBL)-producing Escherichia, coli and Klebsiella and pneumonia. The firm also developed sulopenem in an oral tablet formulation, sulopenem etzadroxil-probenecid, which is known as oral sulopenem.

ITRM Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-6 913.1%
=
Net Income
$-27m
/
Revenue
$390k
What is Iterum Therapeutics PLC's current Net Margin?

The current Net Margin for Iterum Therapeutics PLC is -6 913.1%, which is in line with its 3-year median of -6 913.1%.

How has Net Margin changed over time?

Over the last 0 months, Iterum Therapeutics PLC’s Net Margin has decreased from -6 913.1% to -6 913.1%. During this period, it reached a low of -6 913.1% on Oct 30, 2025 and a high of -6 913.1% on Oct 30, 2025.

Back to Top